fda d.i.s.c.o.: niraparib in ovarian cancer
Published 3 months ago • 15 plays • Length 6:00Download video MP4
Download video MP3
Similar videos
-
5:58
fda d.i.s.c.o.: niraparib in ovarian cancer transcript
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
6:25
niraparib maintenance therapy for ovarian cancer
-
2:35
clinical use of niraparib in ovarian cancer
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
6:31
prima: frontline niraparib maintenance therapy in ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
4:29
case 1: use of niraparib in ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
1:44
the delivery of niraparib and rucaparib as ovarian cancer treatment options
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
3:26
niraparib monotherapy in late-line ovarian cancer
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
1:13
comparison of trials of niraparib, olaparib and rucaparib in ovarian cancer